Mariner
CORT icon

Mariner’s Corcept Therapeutics CORT Stock Holding History

Mariner’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Sell
6,006
-13,759
-70% -$514K ﹤0.01% 3042
2025
Q4 		$745K Sell
19,765
-7,975
-29% -$626K ﹤0.01% 2165
2025
Q3 		$2.31M Buy
27,740
+9,068
+49% +$656K ﹤0.01% 1350
2025
Q2 		$1.37M Buy
18,672
+1,455
+8% +$105K ﹤0.01% 1584
2025
Q1 		$1.97M Buy
17,217
+3,855
+29% +$235K ﹤0.01% 1256
2024
Q4 		$673K Buy
13,362
+1,601
+14% +$83.9K ﹤0.01% 1943
2024
Q3 		$542K Sell
11,761
-183
-2% -$6.5K ﹤0.01% 2069
2024
Q2 		$388K Buy
+11,944
New +$327K ﹤0.01% 2249

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Mariner's CORT Position: Q1 2026 in Review

Mariner reduced its Corcept Therapeutics (CORT) stake by 70% in Q1 2026, selling an estimated $514K and leaving 6,006 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #3042.

Mariner first reported a position in CORT in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.31M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Mariner held 6,006 shares of Corcept Therapeutics worth $242K as of Q1 2026.
  • Mariner sold 13,759 Corcept Therapeutics shares in Q1 2026, an estimated $514K.
  • Corcept Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3042 holding.
  • Mariner first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Mariner's Corcept Therapeutics position peaked at $2.31M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.